ASKA Pharmaceutical Co., Ltd.

TOKYO, June 27, 2024 /PRNewswire/ -- Dioseve Inc. (Headquarters: Tokyo; CEO: Kazuma Kishida; hereinafter "the Company"), aiming to develop assisted reproductive technology using oocytes derived from iPS cells, has raised 7 million USD. This was achieved through third-party allotment of shares to six VC and CVC firms, including lead investors Spiral Capital and Archetype Ventures, existing investor ANRI, a pharmaceutical company ASKA Pharmaceutical Co., Ltd. and other investors. This funding will be used to advance research and development and expand the workforce for global expansion. With this round, the total funds raised to date amount to approximately 10 million USD. Investors (in no particular order, titles omitted) Spiral Capital Inc. Archetype Ventures LLC ANRI Inc. (existing investor) DG Daiwa Ventures Inc. Future Venture Capital Co., Ltd. (ASKA Innovation Fund*1) QR Investment Inc. (Hokuriku Regional Venture Fund*2) Two individual investors *1. The Common name for the "ASKA Innovation Investment Limited Partnership," co-managed by ASKA Pharmaceutical Co., Ltd. and Future Venture Capital Co., Ltd. *2. The Common name for the "Hokuriku Regional Venture Investment Limited Partnership," co-managed by QR Investment Inc. (a subsidiary of Hokugin Financial Holdings Inc.) and Carbon Ventures Inc. (a subsidiary of Mitsutani Sangyo Co., Ltd.) About the Pipeline The Company's main pipeline is the provision of a new infertility treatment using the "DIOLs" technology. This method involves introducing specific genes into iPS cells to produce oocytes in a short period, without expensive growth factors or advanced techniques required by existing production methods, enabling oocyte production in cheap and large quantities. Significance of the Technology Assisted reproductive technology has seen little innovation since the invention of IVF 45 years ago, and fertility largely depends on individual conditions and age. Consequently, many women face life plans based on optimal reproductive age and must choose between a career or having children. By applying this technology in assisted reproductive medicine, we aim to free couples from "not knowing if they can have children" and the constraints of optimal reproductive age, offering them the choice to become mothers at their desired time. Company Overview Company Name: Dioseve Inc. Headquarters: 1-17-8 Shin-Kiba, Koto-ku, Tokyo Mitsui Link Lab Shin-Kiba 2, Room 223 CEO: Kazuma Kishida Established: June 30, 2021 Business: Development of assisted reproductive technology using oocytes derived from iPS cells Website: SOURCE Dioseve, Inc.

Dublin, May 10, 2021 (GLOBE NEWSWIRE) -- The "Cervical Dysplasia Market Share, Size, Trends, Industry Analysis Report, By Type; By End-Use, By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering. The global cervical dysplasia market size is expected to reach USD 936.4 million by 2028 according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.The rising prevalence of cervical cancer and awareness regarding its early diagnosis is the key cervical dysplasia industry impacting factors. As per the report published by World Health Organization, in 2018, worldwide there were around 5, 70,000 new cases of cervical cancer, and more than 3,11,000 deaths were recorded. It also reported that HPV is the most common causal factor for cervical dysplasia among women.Moreover, Cervical Awareness Month was introduced by the U.S. Congress, in 2019, to declare the month of January dedicated to the patients suffering from cervical cancer in the market. National Cervical Cancer Coalition under government control was responsible to highlight issues related to disease and the importance of early diagnosis. These government-supported initiatives are bound to increase awareness regarding disease screening and are anticipated to boost the market growth for cervical dysplasia.Market participants such as Qiagen N.V., Abbott Laboratories, Hologic, Inc., Quest Diagnostics, DYSIS Medical Ltd, Micromedic Technologies Ltd., OncoHealth Corporation, Inc., CooperSurgical Inc., and Roche are some of the key players operating in the global market for cervical dysplasia. The companies in the marketplace for cervical dysplasia are focussing on collaborations and agreement to survive in the highly regulated market with huge patient unmet needs.For instance, in January 2020, both Japan pharmaceutical giants ASKA Pharmaceutical and KinoPharma entered into a collaborative agreement for the development and commercialization of drug candidates for cervical dysplasia in the market, which is under preclinical phase under KinoPharma. Under the agreement, ASKA would obtain exclusive rights to sell the drug in the Japanese market and will help later in co-developing potential drug candidates and KinoPharma in return will receive upfront payments for the exclusive licensing.Earlier, in July 2019, Roche expanded its portfolio of offerings under the Global Access Program to include HPV, and Mycobacterium tuberculosis diagnostic products for the emerging countries, particularly in countries where the prevalence of HPV is highest. This expansion is an attempt towards cost-effective treatments for cervical dysplasia in resource constraint countries and to implement multiple large-scale programs.The publisher has segmented the cervical dysplasia market report on the basis of type, end-use, and region:Cervical Dysplasia, by Type Outlook Cervical Dysplasia, by End-Use Outlook Cervical Dysplasia, by Regional Outlook Key Topics Covered: 1. Introduction1.1. Report Description1.2. Stakeholders2. Executive Summary2.1. Market Highlights3. Research Methodology3.1. Overview3.2. Data Sources4. Cervical Dysplasia Market Insights4.1. Cervical Dysplasia - Industry snapshot4.2. Cervical Dysplasia Market Dynamics4.3. Porter's Five Forces Analysis4.4. PESTLE Analysis4.5. Cervical Dysplasia Market Industry trends5. Cervical Dysplasia Market Assessment by Type5.1. Key Findings5.2. Introduction5.3. Diagnostic Tests5.4. Diagnostic Devices5.5. Colposcope6. Global Cervical Dysplasia Market, by End-Use6.1. Key Findings6.2. Introduction6.3. Hospitals6.4. Diagnostic Centers6.5. Ambulatory Surgical Centers7. Cervical Dysplasia Market Assessment by Geography7.1. Key findings7.2. Introduction7.3. Cervical Dysplasia Market - North America7.4. Cervical Dysplasia Market - Europe7.5. Cervical Dysplasia Market - Asia-Pacific7.6. Cervical Dysplasia Market - Middle East & Africa7.7. Cervical Dysplasia Market - Latin America8. Competitive Landscape8.1. Expansion and Acquisition Analysis8.2. Partnerships/Collaborations/Agreements/Exhibitions9. Company Profiles9.1. Qiagen N.V.9.2. Abbott Laboratories9.3. Hologic, Inc.9.4. Quest Diagnostics9.5. DYSIS Medical Ltd.9.6. Micromedic Technologies Ltd.9.7. OncoHealth Corporation, Inc.9.8. CooperSurgical Inc.9.9. Roche9.10. Karl Kaps GmbH & Co. KG For more information about this report visit

Clarivate published its annual “Drugs to Watch” list, and cited four drugs that it expects to be blockbusters—projected to bring in $1 billion in sales annually. There is a possible snag, though—one may struggle to get approved. Biogen and Eisai’s Aducanumab for Alzheimer’s Disease Earlier this year, the U.S. Food and Drug Administration (FDA) extended the review period for Biogen and Eisai's Biologic License Application (BLA) for aducanumab for Alzheimer’s disease. The drug has been fraught with controversy—and unexpected hopes. The decision by the FDA on the drug application was expected on March 7, but is now delayed until June 7, 2021. In March 2019, Biogen and Tokyo-based Eisai, announced they were discontinuing the global Phase III clinical trials, ENGAGE and EMERGE, of aducanumab in patients with mild cognitive impairment for Alzheimer’s and mild Alzheimer’s dementia. They were also discontinuing the EVOLVE Phase II trial and the long-term extension PRIME Phase Ib trial. An independent data monitoring committee indicated they were unlikely to hit their primary endpoint. It appeared to be the final nail in the amyloid theory of Alzheimer’s disease. Aducanumab is an antibody targeting beta-amyloid, one of the proteins that accumulates in the brains of Alzheimer’s patients. But in October 2019, the two companies announced plans to pursue regulatory approval for the drug. It turned out, the Phase III EMERGE trial met its primary endpoint, showing a significant decrease in clinical decline. Biogen presented the findings in the final data analysis in a December conference, and although there was still some skepticism about the overall data, it did appear to be enough to a BLA and the company planned to do so in the second quarter of 2020. What they presented was that the Phase III EMERGE trial met its primary endpoint, showing a significant decrease in clinical decline. Biogen said the data from a subset of patients that received a high enough dose of the drug had significant benefits on measures of cognition and function, including memory, orientation, and language, as well as benefits on activities of daily living. Although many had issues with some of the data, which was very complex, the companies felt they had a strong enough case to submit it to the FDA and were expected to do so this spring. Then, in April 2020, they announced that although the company had begun to submit parts of the BLA, they did not expect to complete it until the third quarter of this year. The submission was completed in August 2020 with ongoing collaboration with the FDA and include data from the Phase III EMERGE and ENGAGE trials, as well as the Phase Ib PRIME study. Biogen has also requested Priority Review. In November 2020, the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee slammed the drug submission, voting 1 yes, 8 no and 2 uncertain on the question, “Does Study 302 (EMERGE), viewed independently and without regard for Study 301 (ENGAGE), provide strong evidence that supports the effectiveness of aducanumab for the treatment of Alzheimer’s disease?” It also voted 0 yes, 7 no and 4 uncertain on whether Study 103 (PRIME) supported the effectiveness of the drug. Again and again, the committee voted against the drug. Apparently the newest delay is related to the FDA requesting additional analyses and clinical data. Biogen complied, and the FDA considered it a Major Amendment to the application, thus requiring additional review time. If approved, and that seems like a big “if,” the Clarivate analysts describe it as a “monumental opportunity to radically change patient care and transform the market.” UCB’s Bimekizumab For Plaque Psoriasis On September 22, 2020, UCB, based in Brussels, Belgium, announced that the FDA and European Medicines Agency (EMA) accepted the company’s BLA and Marketing Authorization Application (MAA), respectively, for bimekizumab for adults with moderate to severe plaque psoriasis. The submissions were based on positive Phase III data readouts. All met their primary endpoints, demonstrated that patients receiving the drug achieved superior skin clearance at week 16 compared to those who received placebo and those who received AbbVie’s Humira (adalimumab). The drug is a humanized monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL17F, two cytokines that drive inflammation. Probably more importantly, given Humira’s ubiquity, bimekizumab appears to have significantly fewer side effects. The Clarivate team wrote, “While bimekizumab is a late-class entrant providing incremental improvement over existing treatment options, it is expected to have best-in-class efficacy and fewer serious side effects.” Takeda and Myovant’s Relugolix for Prostate Cancer Relugolix is an oral drug to treat prostate cancer. But in addition to that, it is being developed for endometriosis and uterine fibroids in women. The Clarivate analysts believe it’s these three shots on goal that increase the drug’s chances of success. The oral formulation also has advantages over injectable GnRH agonist competitors. On December 18, 2020, the FDA approved the drug, which was developed by Myovant Sciences, under the name Orgovyx, for adults with advanced prostate cancer. It is the first oral gonadotropin-releasing hormone (GnRH) receptor antagonist. In May 2018, Takeda and ASKA Pharmaceutical entered into a licensing deal, granting ASKA exclusive commercialization rights for the drug for uterine fibroids and exclusive development and commercialization rights for endometriosis for Japan. Takeda holds commercial rights in Japan and parts of Asia. Myovant Sciences holds rights in other regions. Myovant Sciences was formed by Takeda and Roivant Sciences in June 2016. Bayer and Merck’s Vericiguat for Chronic Heart Failure On January 20, 2021, the FDA approved Verquvo (vericiguat) to reduce the risk of cardiovascular death and heart failure hospitalization following a hospitalization for heart failure or need for outpatient intravenous (IV) diuretics in adults with symptomatic chronic heart failure and ejection fraction less than 45%. The approval was based on data from the pivotal Phase III VICTORIA trial. The drug is jointly developed by Merck and Bayer AG. Clarivate noted, “Vericiguat’s novel mechanism of action should result in its acceptance as an add-on therapy to existing treatments. It will likely find its niche among high-risk HFrEF patients, become a welcome addition to the treatment armamentarium and expand their treatment options.” Most Read Today